BioLife Solutions (NASDAQ:BLFS) Stock Price Down 5.6%

BioLife Solutions, Inc. (NASDAQ:BLFSGet Free Report)’s stock price traded down 5.6% during trading on Thursday . The stock traded as low as $20.39 and last traded at $20.54. 116,709 shares changed hands during trading, a decline of 71% from the average session volume of 404,102 shares. The stock had previously closed at $21.77.

Analyst Ratings Changes

Several equities research analysts recently commented on the company. Jefferies Financial Group initiated coverage on BioLife Solutions in a report on Thursday, April 4th. They set a “buy” rating and a $22.00 target price on the stock. Benchmark upgraded BioLife Solutions from a “neutral” rating to a “buy” rating and set a $25.00 price objective on the stock in a report on Monday, May 13th. Finally, StockNews.com upgraded BioLife Solutions to a “sell” rating in a report on Friday, May 10th. One equities research analyst has rated the stock with a sell rating and five have assigned a buy rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $23.67.

View Our Latest Stock Report on BLFS

BioLife Solutions Stock Down 1.7 %

The company has a debt-to-equity ratio of 0.05, a current ratio of 2.89 and a quick ratio of 1.77. The stock has a fifty day moving average price of $19.37 and a two-hundred day moving average price of $17.63.

BioLife Solutions (NASDAQ:BLFSGet Free Report) last issued its quarterly earnings results on Thursday, May 9th. The medical equipment provider reported ($0.19) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.25) by $0.06. BioLife Solutions had a negative return on equity of 12.89% and a negative net margin of 45.84%. The business had revenue of $31.73 million during the quarter, compared to the consensus estimate of $29.30 million. During the same period in the previous year, the business earned ($0.27) EPS. On average, equities analysts forecast that BioLife Solutions, Inc. will post -0.44 EPS for the current year.

Insider Activity at BioLife Solutions

In other BioLife Solutions news, insider Sarah Aebersold sold 4,000 shares of the business’s stock in a transaction on Monday, April 1st. The stock was sold at an average price of $17.65, for a total transaction of $70,600.00. Following the completion of the transaction, the insider now owns 65,843 shares in the company, valued at approximately $1,162,128.95. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. In other BioLife Solutions news, insider Sarah Aebersold sold 4,000 shares of the business’s stock in a transaction on Monday, April 1st. The stock was sold at an average price of $17.65, for a total transaction of $70,600.00. Following the completion of the transaction, the insider now owns 65,843 shares in the company, valued at approximately $1,162,128.95. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CMO Todd Berard sold 10,000 shares of the business’s stock in a transaction on Monday, April 15th. The stock was sold at an average price of $15.67, for a total value of $156,700.00. Following the transaction, the chief marketing officer now owns 129,644 shares of the company’s stock, valued at approximately $2,031,521.48. The disclosure for this sale can be found here. Insiders sold 20,729 shares of company stock worth $350,254 in the last 90 days. 2.20% of the stock is currently owned by company insiders.

Institutional Trading of BioLife Solutions

A number of hedge funds and other institutional investors have recently modified their holdings of BLFS. Barclays PLC raised its stake in shares of BioLife Solutions by 205.3% in the 3rd quarter. Barclays PLC now owns 56,968 shares of the medical equipment provider’s stock worth $787,000 after buying an additional 38,311 shares in the last quarter. Charles Schwab Investment Management Inc. raised its stake in shares of BioLife Solutions by 6.3% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 281,998 shares of the medical equipment provider’s stock worth $3,894,000 after buying an additional 16,754 shares in the last quarter. William Blair Investment Management LLC bought a new stake in shares of BioLife Solutions in the 3rd quarter worth $9,335,000. Invesco Ltd. raised its stake in shares of BioLife Solutions by 6.5% in the 3rd quarter. Invesco Ltd. now owns 1,052,065 shares of the medical equipment provider’s stock worth $14,529,000 after buying an additional 64,475 shares in the last quarter. Finally, Rathbones Group PLC bought a new stake in shares of BioLife Solutions in the 3rd quarter worth $1,216,000. Institutional investors own 93.24% of the company’s stock.

About BioLife Solutions

(Get Free Report)

BioLife Solutions, Inc develops, manufactures, and markets bioproduction tools and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company's products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies.

See Also

Receive News & Ratings for BioLife Solutions Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioLife Solutions and related companies with MarketBeat.com's FREE daily email newsletter.